Monte Rosa Advances MRT-6160 Into Phase 2 for Sjögren’s Disease
BOSTON, Massachusetts — September 8, 2026 Monte Rosa Therapeutics, Inc. announced that Novartis has initiated a global Phase 2...
Sjögren’s Disease
Advertisement
Rise Therapeutics Completes Enrollment in R-2487 Rheumatoid Arthritis Trial
ROCKVILLE, Maryland, June 2, 2026 Rise Therapeutics announced the completion of full enrollment in the four-week dose expansion cohort...
Novartis Highlights Immunology Pipeline Progress at EULAR 2026
BASEL, Switzerland, June 1, 2026 Novartis announced that it will present new data from 31 abstracts across its expanding...
FDA Grants Breakthrough Status to Ianalumab in Sjögren’s
Basel, January 16, 2026 — Novartis announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation...
Advertisement
